Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Tenaya Therapeutics (TNYA) is expected to announce its Q3 2025 results on November 5, 2025, with analysts predicting earnings of ($0.15) per share.
• The company's stock recently opened at $1.56 and has seen a significant increase in institutional investment, highlighted by Woodline Partners LP increasing its position by over 30,500%.
• Multiple analysts have given Tenaya Therapeutics a positive outlook, with four ratings of Buy and a target price averaging $6.25, despite one analyst rating it as a Sell.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:00 PM ET.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. On average, analysts expect Tenaya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $1.56 on Wednesday. The firm's 50-day moving average is $1.49 and its two-hundred day moving average is $0.92. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $4.01. The company has a market capitalization of $254.25 million, a PE ratio of -1.63 and a beta of 3.15.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of large investors have recently modified their holdings of the company. Woodline Partners LP increased its position in shares of Tenaya Therapeutics by 30,563.2% in the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Tenaya Therapeutics in the 1st quarter valued at approximately $442,000. Jane Street Group LLC increased its position in shares of Tenaya Therapeutics by 1,958.7% in the 2nd quarter. Jane Street Group LLC now owns 376,068 shares of the company's stock valued at $230,000 after purchasing an additional 357,801 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Tenaya Therapeutics in the 2nd quarter valued at approximately $90,000. Finally, Cerity Partners LLC increased its position in shares of Tenaya Therapeutics by 403.5% in the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock valued at $67,000 after purchasing an additional 88,424 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TNYA has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Chardan Capital reissued a "buy" rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tenaya Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $6.25.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.